1. Home
  2. CVM vs PMN Comparison

CVM vs PMN Comparison

Compare CVM & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVM
  • PMN
  • Stock Information
  • Founded
  • CVM 1983
  • PMN 2004
  • Country
  • CVM United States
  • PMN Canada
  • Employees
  • CVM N/A
  • PMN N/A
  • Industry
  • CVM Biotechnology: Biological Products (No Diagnostic Substances)
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • CVM Health Care
  • PMN Health Care
  • Exchange
  • CVM Nasdaq
  • PMN Nasdaq
  • Market Cap
  • CVM 40.1M
  • PMN 33.7M
  • IPO Year
  • CVM 1987
  • PMN N/A
  • Fundamental
  • Price
  • CVM $0.40
  • PMN $0.89
  • Analyst Decision
  • CVM
  • PMN
  • Analyst Count
  • CVM 0
  • PMN 0
  • Target Price
  • CVM N/A
  • PMN N/A
  • AVG Volume (30 Days)
  • CVM 2.0M
  • PMN 53.0K
  • Earning Date
  • CVM 01-13-2025
  • PMN 11-14-2024
  • Dividend Yield
  • CVM N/A
  • PMN N/A
  • EPS Growth
  • CVM N/A
  • PMN N/A
  • EPS
  • CVM N/A
  • PMN N/A
  • Revenue
  • CVM N/A
  • PMN N/A
  • Revenue This Year
  • CVM N/A
  • PMN N/A
  • Revenue Next Year
  • CVM $152.91
  • PMN N/A
  • P/E Ratio
  • CVM N/A
  • PMN N/A
  • Revenue Growth
  • CVM N/A
  • PMN N/A
  • 52 Week Low
  • CVM $0.36
  • PMN $0.87
  • 52 Week High
  • CVM $3.08
  • PMN $2.61
  • Technical
  • Relative Strength Index (RSI)
  • CVM 38.00
  • PMN 40.96
  • Support Level
  • CVM $0.37
  • PMN $0.88
  • Resistance Level
  • CVM $0.42
  • PMN $0.96
  • Average True Range (ATR)
  • CVM 0.04
  • PMN 0.07
  • MACD
  • CVM -0.00
  • PMN -0.01
  • Stochastic Oscillator
  • CVM 11.83
  • PMN 4.04

About CVM Cel-Sci Corporation

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: